Clinical Trial Update: Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial of pembrolizumab in intermediate-risk recurrent non-muscle invasive bladder cancer has been terminated; results were posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Oxford | Conditions: Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-07-31